期刊文献+

视盘内注射组织凝血酶原激活剂安全性的电生理学评价(英文) 被引量:1

Electrophysiological evaluation of the safety of injection of tissue plasminogen activator into optic nerve in rabbits
下载PDF
导出
摘要 目的:探讨视盘内注射组织凝血酶原激活剂的电生理学安全性。方法:首先将记录VEP的电极植入兔颅骨内。经兔睫状体扁平部将25μg tPA,12.5μg tPA及BSS注入视神经内0.1mL,并与第四组正常眼作比较(n=6)。注入后1,3,7,14和24d行裂隙灯及间接眼底镜检查,记录VEP及ERG。结果:检查未发现视神经内注射tPA对视神经和视网膜有明显的毒性作用和其它损伤。各组VEP第1个波峰的潜伏期分别是24.6±1.5, 24.1±1.9, 24.0±2.0和24.6±1.3mS(P=0.4112);振幅分别是124±42, 145±41, 132±48和117±29μV(P=0.0649)。各组ERG的a波的潜伏期分别是6.0±0.4, 5.9±0.4, 5.9±0.5和5.8±0.3mS(P=0.6279);振幅分别是110±14, 112±15, 110±16和108±11μV(P=0.7248)。b波的振幅分别是151±12,148±14, 144±16和141±20μV(P=0.0957)。结论:经睫状体扁平部向兔视神经内注射tPA,安全可行。 AIM. To investigate the safety of tissue plasminogen activator (tPA) intra optic nerve injection in rabbits. METHODS; Group 1 and 2 (6 eyes in each group) received injection of tPA 25μg and 12. 5μg in 0. lmL balanced saline solution (BSS). Group 3 (6 eyes) received injection of 0. lmL BSS. Six eyes in group four as a normal control received no injection. The eyes were examined with slit lamp biomicroscope, indirect ophthalmoscope, visual evoked potentials (VEP) and electroretinography (ERG) at 1, 3, 7, 14 and 28 days after injection. RESULTS, No evidence of optic nerve or retinal toxicity or physical damage were revealed by ophthalmoscopy, VEP, and ERGs after the injection of tPA into the optic nerve. The means of the latency of the first peak of the VEP were 24. 6±1. 5, 24.1 ±1.9, 24.0±2.0 and 24.6±1.3mS respectively for the above specified groups (P = 0. 4112). The means of the amplitude of the first peak of the VEPs were 124 ± 42, 145 ± 41, 132 ± 48 and 117 ± 291μV respectively ( P = 0. 0649). The means of the latency of awaves were 6. 0 ± 0. 4, 5.9 ± 0.4, 5.9 ± 0.5 and 5.8± 0.3 mS respectively (P= 0. 6279). The means of the amplitude of a-waves were 110 ± 14, 112 ± 15, 110 ± 16 and 108 ± 11μV respectively (P= 0.7248). The means of the amplitude of b-waves were 151 ± 12, 148 ± 14, 144 ± 16 and 141 ± 20μV respectively ( P = 0. 0957). CONCLUSION : Injection of tPA upto 25μg in 0.1 mL into optic nerve is well tolerated. KE
出处 《国际眼科杂志》 CAS 2009年第8期1431-1434,共4页 International Eye Science
关键词 组织凝血酶原激活剂 视神经内注射 视网膜中央静脉阻塞 VEP ERG retinal vein occlusion tissue plasminogen activator intra optic nerve injection VEP ERG
  • 相关文献

参考文献1

二级参考文献35

  • 1Orth DH, Patz A. Retinal branch vein occlusion. Surv Ophthalmol 1978;22(6):357-376
  • 2The Central Vein Occlusion Study Group. Baseline and early natural history report. Arch Opbthalmol 1993 ; 111 ( 8 ) : 1087-1095
  • 3The Central Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion.Arch Ophthalmol 1997 ; 115 (4) : 486-491
  • 4Hayreh SS. Management of central retinal vein occlusion. Ophthalmologica 2003;217(3) :167- 188
  • 5Williamson TH. Central retinal vein occlusion: what's the story?Br J Ophthalmol 1997 ;81 ( 8 ) :698-704
  • 6The Central Vein Occlusion Study Group N report. A randomized clinical study of early panretinal photocoagulation for ischemic central vein occlusion. Ophthalmology 1995 ; 102 ( 10 ) : 1434-1444
  • 7The Central Vein Occlusion Study Group M report. Evaluation of grid pattern photocoagulation for macular edema in central vein oeclusion. Ophthalmology 1995 ; 102(10) : 1425-1433
  • 8McAllister IL, Constable IJ. Laser-induced chorioretinal venous anastomosis for treatment of nonischemic central retinal vein occlusion. Arch Ophthalmol 1995 ; 113 (4) : 456 -462
  • 9Fekrat S, Goldverg MF, Finkelstein D. Laser-induced ehorioretinal venous anastomosis for nonischemic central or branch retinal vein occlusion. Arch Ophthalmol 1998 ; 116 ( 1 ) :43-52
  • 10Browning DJ, antoszyk AN. Laser chorioretinal venous anastomosis for nonischemic central retinal vein occlusion. Ophthalmology 1998; 105 (4) :670-679

同被引文献16

  • 1甘晓玲.弱视的定义、分类及疗效评价标准[J].中国斜视与小儿眼科杂志,1996,4(3):97-97. 被引量:1013
  • 2付晶,成娟娟,卢炜.屈光不正性弱视和正常儿童立体视觉的临床观察[J].眼科,2004,13(5):280-283. 被引量:29
  • 3中华医学会眼科学会弱视斜视防治学组.儿童弱视流行病学调查资料[J].中华眼科杂志,1985,21:31-31.
  • 4中华眼科学会全国儿童斜视弱视防治学组.弱视普查诊断标准[J].中华眼科杂志,1985,:2-2.
  • 5von Noorden GK.Amblyopia in humans and clinical relevance of animal models,Wenner Gren Center Symposium,Strabismus and Amblyopia[M].Great Britain:The Macmillan Press Ltd,1988:169.
  • 6Weber JL.Amblyopia:prevalence,natural history,functional effects and treatment[J].Clin Exp Optomet,2005,88(6):365-366.
  • 7Schiller PH.The central visual system[J].Vision Res,1986,26:1351-1386.
  • 8Thompson B,Aaen-Stockdale CR,Mansouri B,et al.Plaid perception is only subtly impaired in strabismic amblyopia[J].Vision Res,2008,48(11):1307-1314.
  • 9Lai YH,Hsu HT,Wang HZ,et al.The visual status of children ages 3 to 6 years in the vision screening program in Taiwan[J].J AAPOS,2009,13(1):58-62.
  • 10Dobson V,Miller JM,Clifford-Donaldson CE,et al.Associations between anisometropia,amblyopia,and reduced stereoacuity in a school-aged population with a high prevalence of astigmatism[J].Invest Ophthalmol Vis Sci,2008,49(10):4427-4436.

引证文献1

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部